# Zephyr AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zephyr-ai

- Industry: Biotechnology
- Headquarters: McLean, US
- Website: www.zephyrai.bio/
- Total disclosed funding: $130M
- Latest round: Series A (Oct 27, 2023)
- Investors on record: 8

## About

Based in Virginia, US, and founded in 2020 by co-founders Grant Verstandig, Yisroel Brumer, and Jeff Sherman, Zephyr AI, Inc., aka Zephyr, operates as a provider of a platform based on AI that leverages enormous amounts of complicated data and unique algorithms to uncover new insights and possibilities in the healthcare vertical. In March 2024, Zephyr AI, Inc. raised USD 111 million in Series A funding from EPIQ Capital Group, Eli Lilly & Company Foundation, and Revolution Ventures. The Series A funding valued Zephyr AI, Inc. at USD 387.08 million post-money. As of April 2024, the company is led by its interim CEO, Jeff Sherman.

The firm offers a platform that transforms heterogeneous data into useful information that has applications in drug development, repurposing and rescue, clinical trial design and support, precision treatment recommendations, disease prevention, and others.

The business intends to use the March 2024 funding for the expansion of analytical capabilities, data collection enrichment, and team growth acceleration.

## Funding rounds

- Series A, Oct 27, 2023, $111M — Revolution Ventures, Eli Lilly & Company Foundation, EPIQ Capital Group
- Seed, Jan 28, 2022, $18M — MedStar Health Pension Fund, BoxGroup, AME Cloud Ventures, Lerner Enterprises, M-Cor Holdings

## Investors

- MedStar Health Pension Fund — Seed
- BoxGroup (https://capitalatlas.ai/funds/boxgroup) — Seed
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Seed
- Lerner Enterprises — Seed
- M-Cor Holdings — Seed
- Revolution Ventures (https://capitalatlas.ai/funds/revolution-ventures) — Series A
- Eli Lilly & Company Foundation — Series A
- EPIQ Capital Group — Series A